Verrica (VRCA) COO David Zawitz Buys 6,000 Shares

What Happened
David Zawitz, Chief Operating Officer of Verrica Pharmaceuticals Inc. (VRCA), reported a purchase of 6,000 common shares on 2026-08-17 at a weighted average price of $4.98 per share, for a total reported cost of $29,880. This filing shows a direct purchase (transaction code P), which is a purchase by an insider rather than a sale.

Key Details

• Transaction date: 2026-08-17 (reported on Form 4 filed 2026-08-18). Filing appears timely (one day after the transaction).
• Price: weighted average $4.98 per share; footnote indicates purchases occurred at prices ranging from $4.90 to $5.00.
• Shares acquired: 6,000; total reported value $29,880.
• Post-transaction holdings: not specified in the information provided in this summary.
• Notable footnote: The reported $4.98 is a weighted average. The reporting person will provide details on the number of shares bought at each price within the $4.90–$5.00 range upon request.
• No 10b5-1 plan, gift, or tax-withholding indication was provided in the supplied data.

Context
This was an open-market/private purchase reported by an executive (code P). Insider purchases are often viewed by investors as more informative than routine sales, but they do not by themselves prove future stock performance. The filing simply documents the insider’s acquisition and includes a footnote clarifying the trade occurred in multiple transactions within a narrow price range.